CRISPR Therapeutics Eyes Late-Stage Trials as Key Data and CASGEVY Demand Build
CRISPR Therapeutics reported progress in clinical trials for zugo-cel and CTX611, with positive early responses and completed enrollment, respectively. CASGEVY demand reached near $100M revenue run rate. The company expects key data readouts by year-end and in 2024, including CTX611 Phase II results and early data for CTX340 and alpha-1 antitrypsin programs.


